

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Which of the following metrics was significantly improved with the addition of zolbetuximab to first-line chemotherapy for patients with advanced HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in the Phase III SPOTLIGHT trial?
  - Overall response rate
  - Progression-free survival and overall survival
  - Progression-free survival, overall survival and response rate
- Which of the following statements best describes the frequency of any-grade adverse events with durvalumab/tremelimumab compared to sorafenib in the Phase III HIMALAYA trial?
  - Frequency was significantly decreased with durvalumab/tremelimumab
  - Frequency was significantly increased with durvalumab/tremelimumab
  - Frequency was similar between durvalumab/tremelimumab and sorafenib
- What was the rate of interstitial lung disease (ILD) with trastuzumab deruxtecan for Western patients in the Phase II DESTINY-Gastric02 trial with advanced HER2-positive gastric or GEJ cancer whose disease had progressed after a trastuzumab-containing regimen?
  - No ILD was observed
  - Approximately 8%
  - Approximately 30%
- Which of the following statements best describes overall survival results with tislelizumab compared to sorafenib for patients with previously untreated hepatocellular carcinoma in the Phase III RATIONALE 301 trial?
  - Tislelizumab was inferior to sorafenib
  - Tislelizumab was noninferior to sorafenib
  - Tislelizumab was superior to sorafenib
- Which of the following types of toxicity was most commonly observed with the addition of zolbetuximab to chemotherapy for patients with previously untreated HER2-negative advanced gastric/GEJ adenocarcinoma in the Phase III SPOTLIGHT trial?
  - Ocular
  - Neurologic
  - Hematologic
  - Gastrointestinal